You are here

givosiran

FDA's rapid review pace nets an early approval for Alnylam's second drug

Biopharma Dive

Wed, 11/20/19 - 10:51 pm

Alnylam's givosiran reduces mean porphyria attacks by 74% in Phase III

BioCentury

Fri, 04/12/19 - 11:33 pm

acute hepatic porphyria

2 Biotechs With Big Dates in April

Motley Fool

Sat, 03/30/19 - 01:04 pm

Intercept Pharmaceuticals

Data in Hand, Alnylam To Seek OK For Second RNAi Drug

Xconomy

Wed, 03/6/19 - 10:07 am

acute hepatic porphyria

Upcoming events – Fibrogen and Alnylam look to broaden their horizons

EP Vantage

Sat, 03/2/19 - 12:44 pm

Duchenne Muscular Dystrophy

Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug

Marketwatch

Mon, 10/15/18 - 12:05 pm

acute hepatic porphyria

Alnylam, with positive data on second gene-silencing drug, plans filing to FDA

Stat

Thu, 09/27/18 - 10:12 am

acute hepatic porphyrias

Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?

Yahoo/Motley Fool

Mon, 01/15/18 - 09:35 am

Alnylam lines up Phase 3 for another RNAi drug

BioPharma Dive

Tue, 06/27/17 - 10:33 am

acute hepatic porphyrias